Clinical Trial Update: Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tivantinib with or without erlotinib in metastatic or locally advanced renal cell carcinoma that cannot be surgically removed; study co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Cancer
• Renal Cell Carcinoma
• Type 2 Papillary Renal Cell Carcinoma
• Type Papillary Renal Cell Carcinoma

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)
• tivantinib (tivantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-01-03